Skip to main content

Table 1 Baseline demographics

From: Prognostic prediction across a gradient of total tumor volume in patients with hepatocellular carcinoma undergoing locoregional therapy

Number of patients 786
Age (mean ± SD years; range) 67 ± 12 (27-92)
Male/female (%) 73/27
Underlying liver disease (%)  
   HBsAg-positive 393 (50)
   HBsAg-negative  
Anti-HCV-positive 265 (34)
Anti-HCV-negative 128 (16)
Tumoral characteristics (%)  
   Single lesion 500 (64)
   Multi-nodular lesions 286 (36)
   Maximal tumor diameter  
≤ 5 cm 566 (72)
>5 cm 220 (28)
Ascites (%)  
   Yes 101 (13)
   No 685 (87)
Serum AFP level (ng/mL) (%)  
   Median (range) 29 (2-10,032,600)
   <20 344 (44)
   20 - 400 288 (37)
   >400 154 (19)
Performance status (%)  
   ECOG scale 0 590 (75)
   ECOG scale 1-3 196 (25)
Serum biochemistries (mean ± SD)  
   Albumin (g/dL) 3.7 ± 0.6
   Bilirubin (mg/dL) 1.1 ± 1.0
   Creatinine (mg/dL) 1.3 ± 3.2
   Prothrombin time INR 1.1 ± 0.3
   ALT (IU/L) 69 ± 68
   AST (IU/L) 52 ± 44
Child-Pugh-Turcotte class (%)  
   A 639 (81)
   B 147 (19)
MELD score (mean ± SD; range) (%) 9.3 ± 3.1 (6.4-23.9)
   <8 336 (43)
   8-11 215 (27)
   >11 235 (30)
Vascular invasion (%)  
   No 699 (9)
   Yes 87 (91)
CLIP staging (%)  
   Score 0 266 (34)
   Score 1 276 (35)
   Score 2 141 (18)
   Score 3 66 (8)
   Score 4 or 5 37 (5)
Total tumor volume (cm3) (%)  
   Mean ± SD (range) 177 ± 436 (0.1-3,591)
   Median 21
   <10 297 (38)
   10-50 226 (29)
   50-200 121 (15)
   200-500 57 (7)
   >500 85 (11)
Treatment (%)  
   PAI or PEI 79 (10)
   RFA 221 (28)
   TACE 471 (60)
   More than one methods 15 (2)